Evidence map›Paper›PMID 36929282›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2023

CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory Study.

Martin K R Svačina, Anika Meißner, Finja Schweitzer, Alina Sprenger-Svačina, Ines Klein, Hauke Wüstenberg, Felix Kohle, Helene L Walter, Michael Schroeter, Helmar C Lehmann

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Martin K R SvačinaDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener Straße 62, Cologne, 50937, Germany.
Anika MeißnerDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener Straße 62, Cologne, 50937, Germany.
Finja SchweitzerDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener Straße 62, Cologne, 50937, Germany.
Alina Sprenger-SvačinaDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener Straße 62, Cologne, 50937, Germany.
Ines KleinDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener Straße 62, Cologne, 50937, Germany.
Hauke WüstenbergDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener Straße 62, Cologne, 50937, Germany.
Felix KohleDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener Straße 62, Cologne, 50937, Germany.
Helene L WalterDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener Straße 62, Cologne, 50937, Germany.
Michael SchroeterDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener Straße 62, Cologne, 50937, Germany.
Helmar C LehmannDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener Straße 62, Cologne, 50937, Germany. helmar.lehmann@uk-koeln.de.
University Hospital Cologne · DEUniversity of Cologne · DEKlinikum Leverkusen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Availability of COVID-19 mRNA vaccine for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg) raises the question of whether COVID-19 mRNA vaccine influences disease activity or IVIg-mediated immunomodulation in CIDP. In this exploratory study, blood samples of CIDP patients on IVIg treatment were longitudinally analyzed before and after vaccination with a COVID-19 mRNA vaccine. A total of 44 samples of eleven patients were characterized at four timepoints by ELISA and flow cytometry in terms of immunomarkers for disease activity and IVIg-immunomodulation. Apart from a significantly lower expression of CD32b on naïve B cells after vaccination, no significant alteration of immunomarkers for CIDP or IVIg-mediated immunomodulation was observed. Our exploratory study suggests that COVID-19 mRNA vaccine does not have a relevant impact on immune activity in CIDP. In addition, immunomodulatory effects of IVIg in CIDP are not altered by COVID-19 mRNA vaccine. This study was registered in the German clinical trial register (DRKS00025759). Overview over the study design. Blood samples of CIDP patients on recurrent IVIg treatment and vaccination with a COVID-19 mRNA vaccine were obtained at four timepoints for cytokine ELISA and flow cytometry, to assess key cytokines and cellular immunomarkers for disease activity and IVIg-immunomodulation in CIDP.

Indexed as

COVID-19Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingCOVID-19 VaccinesHumansImmunoglobulins, IntravenousRNA, MessengerVaccinationCOVID-19 VaccinesImmunoglobulins, IntravenousRNA, MessengerCytokinesFcγRIIb/CD32bImmune CellsImmune NeuropathyVaccine Interaction

Identifiers

PMID36929282
PMCPMC10018581
OpenAlexW4327684397

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read36
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.